Proteins involved in nerve cell communication — via the release of signaling molecules such as dopamine, which is abnormally low in people with Parkinson’s disease — are “spring-loaded” in advance of a triggering signal by calcium, supercomputer simulations showed. These findings, which were consistent with current experimental data, may help…
A four-week, task-specific exercise program done at home can improve turning ability and balance, and ease disease severity for people with early- to mid-stage Parkinson’s, a small study suggested. This Parkinson’s exercise program focuses explicitly on rotating those parts of the body most involved in turning. It may be…
Impairment due to Parkinson’s disease of the involuntary nervous system, which controls heart rate, among other bodily functions, was associated with worse outcomes after five years — particularly relative to dementia, daily motor activities, and quality of life, a study suggested. In fact, worse cardiovascular assessment scores were linked to…
Denali Therapeutics‘ DNL201, an investigational therapy for Parkinson’s disease, was well tolerated in healthy volunteers and patients, and showed evidence of engaging its target protein, according to multiple preclinical and clinical studies. LRRK2, a protein associated with Parkinson’s, is also the target of BIIB122 (formerly DNL151), which is…
People of African ancestry in South Africa with Parkinson’s disease have more copies of mitochondrial DNA within their cells than do people of similar ancestry without the condition, a study discovered. These findings contrast with studies in patients of Asian and European ancestry, who have fewer copy numbers than…
The female hormone known as chorionic gonadotropin (hCG) protects nerve cells in the brain that are lost in people with Parkinson’s disease, a mouse model study showed, reportedly for the first time. These findings suggest that hCG may be an effective therapeutic agent to slow Parkinson’s progression, its researchers…
Iron buildup in the region of the brain largely affected in Parkinson’s disease did not contribute to disease development or progression, an MRI study has found. In contrast, iron accumulation was related to disease duration and the use of levodopa, a standard Parkinson’s therapy, a finding that needs…
Using a wrist-worn device that continuously monitors body movements, a U.S. study has found 85% of people with Parkinson’s disease experience  bradykinesia — abnormally slow movements — in the morning. Even after the first daily dose of levodopa, a standard Parkinson’s therapy, 64% had continued morning bradykinesia. Moreover,…
BlueRock Therapeutics has completed full enrollment in its open-label Phase 1 study evaluating the safety and preliminary efficacy of its investigational cell-based therapy BRT-DA01 for advanced Parkinson’s disease. The therapy is designed to ease motor symptoms in Parkinson’s patients who do not fully respond to regular medications. The…
NRG Therapeutics has received a £2.68M (about $3.4 million) award to support preclinical work into small molecule disease-modifying therapies for neurodegenerative conditions such as Parkinson’s disease. The two-year Biomedical Catalyst award given the company is for early stage research in treatments to protect mitochondria in the brain, and is partly funded…
Get regular updates to your inbox.
